Tom Petzinger, board member, is Executive Vice President of Knopp Neurosciences Inc. and CEO of LaunchCyte LLC, a founder of Immunetrics and five other life science companies. He also serves on the boards of Reaction Biology Corp., Crystalplex Corp., Celsense Inc., and the Pennsylvania Biotechnology Association. Prior to co-founding LaunchCyte, he spent 22 years at The Wall Street Journal in several capacities, including Washington Economics Editor, Deputy Washington Bureau Chief, and weekly columnist. The author of three books, Tom holds a B.S. in journalism from Northwestern University, where he was a Richter Undergraduate International Scholar.
Martin Brecher, M.D., board member, is currently the Chief Medical Officer at SK Life Sciences. He has 17 years experience conducting clinical drug trials and managing drug development. Previously a medical science director at AstraZeneca, he led the programs which resulted in new indications for Seroquel for mania, bipolar depression, unipolar depression, generalized anxiety disorder, maintenance treatment in schizophrenia, maintenance treatment in bipolar disorder and a new formulation of Seroquel. Prior to joining industry Dr. Brecher worked at the FDA for two years. He was on the faculty of the Department of Psychiatry at SUNY Downstate for 10 years where he conducted electrophysiological research in schizophrenic patients. Dr. Brecher is a graduate of the MIT and also received a Doctor of Medical Science degree from SUNY Downstate and an MBA from the Wharton School of Business. He has over 30 peer reviewed publications in the fields of electrophysiology and psychopharmacology.
Steven Chang, M.S., CEO, board member, is a successful technology
entrepreneur with more than 18 years of experience in developing complex
computer models, optimization algorithms, and data mining systems. He was
the founding Chairman of the board of directors for SCAI (Society for
Complexity in Acute Illnesses). As founding CEO of Futuristics Labs, Steve
raised two rounds of financing totaling over $10 million. Futuristics'
proprietary technologies enabled real-time ad hoc query processing on
terabyte sized databases with no loss in data resolution. Prior to founding
Futuristics, Steve headed up the Intelligent Software Systems group at
Westinghouse/CBS Corporation's Science and Technology Center and developed
decision optimization and computer modeling systems that were successfully
deployed in many Fortune 500 companies, including Kraft Foods,
Colgate-Palmolive, Nestle, and Airborne Express. He was also instrumental in
establishing the first Westinghouse presence on the Internet and was the
recipient of two George Westinghouse Signature Awards for Excellence. Steve
attained both BS and MS degrees in Electrical Engineering from the
Rensselaer Polytechnic Institute.
Tom Petzinger, board member, is Executive Vice President of Knopp Neurosciences Inc. and CEO of LaunchCyte LLC, a founder of Immunetrics and five other life science companies. He also serves on the boards of Reaction Biology Corp., Crystalplex Corp., Celsense Inc., and the Pennsylvania Biotechnology Association. Prior to co-founding LaunchCyte, he spent 22 years at The Wall Street Journal in several capacities, including Washington Economics Editor, Deputy Washington Bureau Chief, and weekly columnist. The author of three books, Tom holds a B.S. in journalism from Northwestern University, where he was a Richter Undergraduate International Scholar.
Martin Brecher, M.D., board member, is currently the Chief Medical Officer at SK Life Sciences. He has 17 years experience conducting clinical drug trials and managing drug development. Previously a medical science director at AstraZeneca, he led the programs which resulted in new indications for Seroquel for mania, bipolar depression, unipolar depression, generalized anxiety disorder, maintenance treatment in schizophrenia, maintenance treatment in bipolar disorder and a new formulation of Seroquel. Prior to joining industry Dr. Brecher worked at the FDA for two years. He was on the faculty of the Department of Psychiatry at SUNY Downstate for 10 years where he conducted electrophysiological research in schizophrenic patients. Dr. Brecher is a graduate of the MIT and also received a Doctor of Medical Science degree from SUNY Downstate and an MBA from the Wharton School of Business. He has over 30 peer reviewed publications in the fields of electrophysiology and psychopharmacology.
Steven Chang, M.S., CEO, board member, is a successful technology
entrepreneur with more than 18 years of experience in developing complex
computer models, optimization algorithms, and data mining systems. He was
the founding Chairman of the board of directors for SCAI (Society for
Complexity in Acute Illnesses). As founding CEO of Futuristics Labs, Steve
raised two rounds of financing totaling over $10 million. Futuristics'
proprietary technologies enabled real-time ad hoc query processing on
terabyte sized databases with no loss in data resolution. Prior to founding
Futuristics, Steve headed up the Intelligent Software Systems group at
Westinghouse/CBS Corporation's Science and Technology Center and developed
decision optimization and computer modeling systems that were successfully
deployed in many Fortune 500 companies, including Kraft Foods,
Colgate-Palmolive, Nestle, and Airborne Express. He was also instrumental in
establishing the first Westinghouse presence on the Internet and was the
recipient of two George Westinghouse Signature Awards for Excellence. Steve
attained both BS and MS degrees in Electrical Engineering from the
Rensselaer Polytechnic Institute.